Axicabtagene ciloleucel is an autologous anti-CD19 CAR T-cell therapy developed for patients with relapsed or refractory B-cell malignancies, particularly diffuse large B-cell lymphoma. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.